They showed that loss of CHD1 induces the transcription factors of GR, BRN2, TBX2, and NR2F1, which are required to promote tumor heterogeneity and resistance to AR inhibitors in CHD1-deficient tumors (22). This evidence concerns the gene NR3C1 and neoplasm.